Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance
Cancer Pathogenesis and Therapy · 2026-05 · 4 (3) · 174-191
DOI: 10.1016/j.cpt.2025.07.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Pathogenesis and Therapy, 2026-05. Verfasst von Abdul Halim Shaikat und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Science and Engineering, International Islamic University Chittagong Chattogram, 4318, Bangladesh. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypoxia, a hallmark of the tumor microenvironment (TME), drives cancer progression through immune modulation, angiogenesis promotion, metabolic reprogramming, and uncontrolled cell proliferation. This review explores the diverse functions of hypoxia-inducible factor (HIF) signaling in cancer development and progression, providing a comprehensive overview of the molecular pathways. HIFs, particularly HIF-1α and HIF-2α, regulate several genes related to cancer hallmarks such as invasion, metabolic reprogramming, angiogenesis, and therapy resistance, thus mediating a significant portion of the hypoxic response. Hydroxylation of proline and asparagine residues in HIF-α subunits, which occurs in an oxygen-dependent manner, serves as a key regulatory mechanism for both their stability and transcriptional function. Notably, this complex interaction is regulated by multiple signaling pathways, including the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK), phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR), and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways. In cancer, HIF signaling affects several aspects of tumor cell biology that contribute to the cancerous characteristics, including angiogenesis induction through the upregulation of vascular endothelial growth factor (VEGF) expression, metabolic reprogramming through the enhancement of the Warburg effect, facilitation of cancer invasion and metastasis by driving epithelial-to-mesenchymal transition (EMT) and matrix remodeling patterns, and mediation of therapeutic resistance partly due to the effects on drug efflux pumps and DNA damage repair. Direct and indirect HIF inhibitors-including small molecules, peptidomimetics, antibodies, and proteolysis-targeting chimeras (PROTACs)-are under preclinical and clinical evaluation for their therapeutic efficacy. Preclinical and early clinical trials have demonstrated significant synergistic effects in inhibiting tumor development when HIF inhibition is combined with traditional therapies (chemotherapy or radiation) or immunotherapies, emphasizing major clinical implications and the potential for improving patient outcomes. Although challenges exist, particularly regarding drug resistance, further research to improve therapeutic efficacy and prolong survival for patients is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Science and Engineering, International Islamic University Chittagong Chattogram, 4318, Bangladesh.
- Pratyasha Health Biomedical Research Center, Dhaka 1230, Bangladesh.
- Department of Pharmacy, Faculty of Life and Earth Science, Jagannath University, Dhaka 1100, Bangladesh.
- Department of Pharmacy, State University of Bangladesh, Dhaka 1461, Bangladesh.
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA.
- Department of Biology, Indiana State University, Terre Haute, IN 47809, USA.
Zitieren
APA
Shaikat, A. H., Azad, S. M. A. K., Tamim, M. A. R., Ullah, M. S., Amin, M. N., Sabbir, M. K., Tarun, M. T. I., Mostaq, M. S., Sabrin, S., Mahmud, M. Z., & Mahmud, M. A. (2026). Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathogenesis and Therapy, 4(3), 174-191. https://doi.org/10.1016/j.cpt.2025.07.003
Vancouver
Shaikat AH, Azad SMAK, Tamim MAR, Ullah MS, Amin MN, Sabbir MK, et al. Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathogenesis and Therapy. 2026;4(3):174-191. doi:10.1016/j.cpt.2025.07.003
BibTeX
@article{Shaikat2026,
author = {Shaikat, Abdul Halim and Azad, S M Asadul Karim and Tamim, Md Azizur Rahman and Ullah, Mohammed Sailim and Amin, Mohammad Nurul and Sabbir, Mofazzal K and Tarun, Md Towhidul Islam and Mostaq, Md Saqline and Sabrin, Shohana and Mahmud, Md Zihad and Mahmud, Md Ashiq},
title = {Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance},
journal = {Cancer Pathogenesis and Therapy},
year = {2026},
volume = {4},
number = {3},
pages = {174--191},
doi = {10.1016/j.cpt.2025.07.003}
}
EUVIMED